Anavex Life Sciences Corp. (AVXL)
- Previous Close
3.8000 - Open
3.7600 - Bid 3.7700 x 600
- Ask 3.8100 x 600
- Day's Range
3.6000 - 3.8000 - 52 Week Range
3.6000 - 10.4500 - Volume
2,053,271 - Avg. Volume
1,264,204 - Market Cap (intraday)
310.385M - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.67
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
www.anavex.comRecent News: AVXL
Performance Overview: AVXL
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVXL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVXL
Valuation Measures
Market Cap
312.03M
Enterprise Value
168.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.30
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.96
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.70%
Return on Equity (ttm)
-31.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.16M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
143.76M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-17.68M
Research Analysis: AVXL
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell